Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors

Talimogene laherparepvec is a first-in-class intralesional oncolytic immunotherapy. In a recent Phase III trial (OPTiM), talimogene laherparepvec significantly improved durable response rate compared with subcutaneous granulocyte–macrophage colony-stimulating factor (GM-CSF). Overall response rate w...

Descripción completa

Detalles Bibliográficos
Autores principales: Dummer, Reinhard, Hoeller, Christoph, Gruter, Isabella Pezzani, Michielin, Olivier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5445176/
https://www.ncbi.nlm.nih.gov/pubmed/28238174
http://dx.doi.org/10.1007/s00262-017-1967-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5445176/
https://www.ncbi.nlm.nih.gov/pubmed/28238174
http://dx.doi.org/10.1007/s00262-017-1967-1

Ejemplares similares